BriaCell Therapeutics Corp. (BCTX) stock
BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ
$3.51−0.08 (-2.23%)
Close on Nov 12, 2026Market cap $30.65MP/E –Yield –
BriaCell Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
BriaCell Therapeutics's R&D Expenses for the twelve months ending Jul 31, 2026 was $29.24M, up 37.4% year over year. For fiscal 2026 it was $29.24M, up 37.4% from the year before. The highest annual figure on record is $29.24M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | $29.24M | +37.4% |
| FY2025 | Jul 31, 2025 | $21.27M | -21.7% |
| FY2024 | Jul 31, 2024 | $27.18M | +77.2% |
| FY2023 | Jul 31, 2023 | $15.34M | +91.2% |
| FY2022 | Jul 31, 2022 | $8.02M | +296.9% |
| FY2021 | Jul 31, 2021 | $2.02M | -16.7% |
| FY2020 | Jul 31, 2020 | $2.43M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | $10.53M | +48.1% |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | $5.97M | +24.0% |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | $6.05M | +6.5% |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | $6.68M | +82.3% |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | $7.11M | +61.4% |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | $4.81M | -37.2% |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | $5.68M | -31.2% |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | $3.67M | -46.5% |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | $4.41M | -14.7% |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | $7.66M | +98.4% |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | $8.26M | +170.4% |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | $6.86M | +110.7% |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | $5.17M | +63.1% |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | $3.86M | +70.2% |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | $3.05M | +78.7% |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | $3.26M | +271.8% |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | $3.17M | +445.6% |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | $2.27M | +101.6% |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | $1.71M | +931.6% |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | $875.64K | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | $580.82K | – |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | $1.13M | – |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | $165.59K | – |
See a number that looks wrong?